-
MabPharm’s CMAB807 Biosimilar Receives Market Approval in Indonesia and Peru
•
Taizhou-based MabPharm Ltd (HKG: 2181), a specialist in monoclonal antibody (mAb) biosimilars, has announced the receipt of market approval for CMAB807, a biosimilar version of Johnson & Johnson’s (J&J, NYSE: JNJ) Remicade (infliximab), in Indonesia, with a similar approval in Peru in July this year. The approval encompasses all six…
-
MabPharm’s Biosimilar Infliximab CMAB807 Receives Market Approval in Peru
•
MabPharm Ltd (HKG: 2181), a biosimilar specialist in monoclonal antibody (mAb) based in Taizhou, has announced that it has received market approval for CMAB807, a biosimilar version of Johnson & Johnson (J&J)’s Remicade (infliximab), in Peru. The approval encompasses all six indications, which include adult ulcerative colitis, ankylosing spondylitis, rheumatoid…
-
Sichuan Kelun Pharmaceutical Submits Biosimilar Cetuximab for NMPA Approval
•
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), has announced a market approval filing for its pipeline candidate A140, a biosimilar version of Merck KGaA/Bristol-Myers Squibb’s (NYSE: MRK/BMS, NYSE: BMY) cetuximab, known under the trade name Erbitux. The…
-
Simcere Pharmaceutical Group Secures Exclusive Rights to CMAB009 in China
•
Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced that its subsidiary, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd, has entered into a cooperation agreement with Taizhou Mabtech Pharmaceutical Ltd, a subsidiary of Mabpharm Ltd (HKG: 2181), focusing on the molecule CMAB009. Under the terms of the deal, Simcere Zaiming has obtained…
-
Jiangxi Jemincare Group Launches Omalizumab Biosimilar CMAB007 in China for Asthma and Dermatology
•
Jiangxi Jemincare Group has overseen the official launch and first prescription of its omalizumab biosimilar, CMAB007, a version of Roche/Genentech’s (SWX: ROG) anti-IgE dermatology and asthma therapy Xolair, in Beijing. The drug’s launch comes less than two months after it received market approval. Therapeutic Applications of OmalizumabOmalizumab is utilized to…
-
MabPharm’s CMAB007 Receives NMPA Approval for IgE-Mediated Asthma Treatment
•
Taizhou-based monoclonal antibody (mAb) biosimliars specialist MabPharm Ltd (HKG: 2181) has announced that it has attained market approval from the National Medical Products Administration (NMPA) for its CMAB007, a biosimilar version of Roche/Genentech’s anti-IgE dermatology and asthma therapy omalizumab (trade name: Xolair). This approval marks the first home-grown therapeutic biologic…
-
Jiangxi Jemincare Group Secures Exclusive Rights to Promote MabPharm’s Biosimilar CMAB007
•
Jiangxi Jemincare Group, a China-based healthcare company, has entered into a licensing agreement with fellow Chinese firm MabPharm Ltd (HKG: 2181) to obtain exclusive promotion rights to CMAB007, a prospective biosimilar of Roche/Genentech’s anti-IgE drug omalizumab, known under the trade name Xolair. The agreement encompasses rights across Greater China, including…
-
MabPharm Files NDA for CMAB009, Biosimilar to Erbitux, Targeting Metastatic Colorectal Cancer
•
Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the filing of a New Drug Application (NDA) for its CMAB009, a biosimilar of Merck KGaA (ETR: MRK)/Bristol-Myers Squibb’s (BMS, NYSE: BMY) cetuximab (trade name: Erbitux). The filing has been accepted for review by the National Medical Products…
-
MabPharm’s CMAB015 Biosimilar Receives NMPA Approval for Clinical Study
•
Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its CMAB015, a biosimilar of Novartis’ Cosentyx (secukinumab). The study will target psoriasis and ankylosing spondylitis. Drug ProfileCosentyx was first approved…
-
MabPharm’s CMAB017 Receives NMPA Approval for Clinical Study in Solid Tumors
•
Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its Category 1 innovative drug candidate CMAB017 in advanced solid tumors. The trial will include patients with colorectal cancer, head and…
